Panomifene

Panomifene

Clinical data
Synonyms	GYKI-13504; EGIS-5650
Identifiers
IUPAC name 2-[2-[4-[(E)-3,3,3-trifluoro-1,2-diphenylprop-1-enyl]phenoxy]ethylamino]ethanol
CAS Number	77599-17-8
PubChem CID	3033654
ChemSpider	2298282
UNII	GCW5E728OC
ChEMBL	CHEMBL2105273
Chemical and physical data
Formula	C25H24F3NO2
Molar mass	427.467 g/mol
3D model (JSmol)	Interactive image
SMILES C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\C(F)(F)F)/C3=CC=C(C=C3)OCCNCCO
InChI InChI=1S/C25H24F3NO2/c26-25(27,28)24(21-9-5-2-6-10-21)23(19-7-3-1-4-8-19)20-11-13-22(14-12-20)31-18-16-29-15-17-30/h1-14,29-30H,15-18H2/b24-23+ Key:MHXVDXXARZCVRK-WCWDXBQESA-N

Panomifene (INN) (former developmental code names GYKI-13504, EGIS-5650) is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group related to tamoxifen that was under development as an antineoplastic agent by Egis Pharmaceuticals and IVAX Drug Research Institute in the 1990s for the treatment of breast cancer but was not marketed. It reached phase II clinical trials before development was terminated. The drug was described in 1981.